Trial Profile
The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 27 May 2019
Price :
$35
*
At a glance
- Drugs Rifaximin (Primary)
- Indications Hepatic encephalopathy
- Focus Therapeutic Use
- 13 Jul 2018 According to a Bausch Health Companies media release, Valeant Pharmaceuticals International changed its name to Bausch Health Companies.
- 10 Mar 2016 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 17 Jul 2015 Planned End Date changed from 1 Jan 2015 to 1 Jan 2016 as reported by ClinicalTrials.gov.